Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18883304 | 0.88 | MAPT (0.80) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL18888491 | 0.83 | MAPT (0.71) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL15228617 | 0.83 | MAPT (0.82) | MAPTTP53POLBGRM5KDM4E | |
| SCHEMBL15228309 | 0.83 | MAPT (0.82) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL29353512 | 0.83 | MAPT (0.82) | MAPTTP53POLBGRM5KDM4E | |
| SCHEMBL16429075 | 0.82 | MAPT (0.80) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL18883299 | 0.80 | MAPT (0.77) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL15228394 | 0.80 | MAPT (0.70) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL15244857 | 0.79 | MAPT (0.73) | MAPTTP53POLBGRM5HCRTR1 | |
| SCHEMBL18883294 | 0.79 | MAPT (0.72) | MAPTTP53POLBGRM5PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | HAVCR2, PCNA, DNMT1 | MAPT 1882/4885TP53 250/4885POLB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.